FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095524269> ?p ?o ?g. }

• W2095524269 endingPage "552" @default.
• W2095524269 startingPage "545" @default.
• W2095524269 abstract "Abstract The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma ( RCC ) progression. Preclinical evidence suggests that baseline elevated tumor glucose metabolism as quantified by FDG ‐ PET ([ 18 F] fluorodeoxy‐glucose positron emission tomography) may predict antitumor activity. Metastatic RCC ( mRCC ) patients refractory to vascular endothelial growth factor ( VEGF ) pathway inhibition were treated with standard dose everolimus. FDG ‐ PET scans were obtained at baseline and 2 weeks; serial computed tomography ( CT ) scans were obtained at baseline and every 8 weeks. Maximum standardized uptake value (SUVmax) of the most FDG avid lesion, average SUVmax of all measured lesions and their corresponding 2‐week relative changes were examined for association with 8‐week change in tumor size. A total of 63 patients were enrolled; 50 were evaluable for the primary endpoint of which 48 had both PET scans. Patient characteristics included the following: 36 (72%) clear cell histology and median age 59 (range: 37–80). Median pre‐ and 2‐week treatment average SUVmax were 6.6 (1–17.9) and 4.2 (1–13.9), respectively. Response evaluation criteria in solid tumors (RECIST)‐based measurements demonstrated an average change in tumor burden of 0.2% (−32.7% to 35.9%) at 8 weeks. Relative change in average SUVmax was the best predictor of change in tumor burden (all evaluable P = 0.01; clear cell subtype P = 0.02), with modest correlation. Baseline average SUVmax was correlated with overall survival and progression‐free survival ( PFS ) ( P = 0.023; 0.020), but not with change in tumor burden. Everolimus therapy decreased SUV s on follow‐up PET scans in mRCC patients, but changes were only modestly correlated with changes in tumor size. Thus, clinical use of FDG ‐ PET ‐based biomarkers is challenged by high variability." @default.
• W2095524269 created "2016-06-24" @default.
• W2095524269 creator A5007052233 @default.
• W2095524269 creator A5025809703 @default.
• W2095524269 creator A5037373285 @default.
• W2095524269 creator A5065248724 @default.
• W2095524269 creator A5075863856 @default.
• W2095524269 creator A5082413734 @default.
• W2095524269 creator A5088131964 @default.
• W2095524269 date "2013-07-10" @default.
• W2095524269 modified "2023-10-16" @default.
• W2095524269 title "<scp>FDG</scp> ‐ <scp>PET</scp> as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer" @default.
• W2095524269 cites W1984947150 @default.
• W2095524269 cites W2004809400 @default.
• W2095524269 cites W2004866251 @default.
• W2095524269 cites W2027639503 @default.
• W2095524269 cites W2033958147 @default.
• W2095524269 cites W2034666877 @default.
• W2095524269 cites W2037844161 @default.
• W2095524269 cites W2072638902 @default.
• W2095524269 cites W2075997152 @default.
• W2095524269 cites W2092349505 @default.
• W2095524269 cites W2101084498 @default.
• W2095524269 cites W2102900043 @default.
• W2095524269 cites W2105460321 @default.
• W2095524269 cites W2107975811 @default.
• W2095524269 cites W2118677643 @default.
• W2095524269 cites W2126289532 @default.
• W2095524269 cites W2128925612 @default.
• W2095524269 cites W2139248078 @default.
• W2095524269 cites W2149026055 @default.
• W2095524269 cites W2149246783 @default.
• W2095524269 cites W2153867442 @default.
• W2095524269 cites W2166140900 @default.
• W2095524269 doi "https://doi.org/10.1002/cam4.102" @default.
• W2095524269 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3799289" @default.
• W2095524269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24156027" @default.
• W2095524269 hasPublicationYear "2013" @default.
• W2095524269 type Work @default.
• W2095524269 sameAs 2095524269 @default.
• W2095524269 citedByCount "51" @default.
• W2095524269 countsByYear W20955242692014 @default.
• W2095524269 countsByYear W20955242692015 @default.
• W2095524269 countsByYear W20955242692016 @default.
• W2095524269 countsByYear W20955242692017 @default.
• W2095524269 countsByYear W20955242692018 @default.
• W2095524269 countsByYear W20955242692019 @default.
• W2095524269 countsByYear W20955242692020 @default.
• W2095524269 countsByYear W20955242692021 @default.
• W2095524269 countsByYear W20955242692022 @default.
• W2095524269 countsByYear W20955242692023 @default.
• W2095524269 crossrefType "journal-article" @default.
• W2095524269 hasAuthorship W2095524269A5007052233 @default.
• W2095524269 hasAuthorship W2095524269A5025809703 @default.
• W2095524269 hasAuthorship W2095524269A5037373285 @default.
• W2095524269 hasAuthorship W2095524269A5065248724 @default.
• W2095524269 hasAuthorship W2095524269A5075863856 @default.
• W2095524269 hasAuthorship W2095524269A5082413734 @default.
• W2095524269 hasAuthorship W2095524269A5088131964 @default.
• W2095524269 hasBestOaLocation W20955242691 @default.
• W2095524269 hasConcept C121608353 @default.
• W2095524269 hasConcept C126322002 @default.
• W2095524269 hasConcept C143998085 @default.
• W2095524269 hasConcept C199374082 @default.
• W2095524269 hasConcept C203092338 @default.
• W2095524269 hasConcept C2775842073 @default.
• W2095524269 hasConcept C2776694085 @default.
• W2095524269 hasConcept C2777472916 @default.
• W2095524269 hasConcept C2778822529 @default.
• W2095524269 hasConcept C2779699572 @default.
• W2095524269 hasConcept C2779984678 @default.
• W2095524269 hasConcept C2781197716 @default.
• W2095524269 hasConcept C2989005 @default.
• W2095524269 hasConcept C535046627 @default.
• W2095524269 hasConcept C55493867 @default.
• W2095524269 hasConcept C71924100 @default.
• W2095524269 hasConcept C86803240 @default.
• W2095524269 hasConceptScore W2095524269C121608353 @default.
• W2095524269 hasConceptScore W2095524269C126322002 @default.
• W2095524269 hasConceptScore W2095524269C143998085 @default.
• W2095524269 hasConceptScore W2095524269C199374082 @default.
• W2095524269 hasConceptScore W2095524269C203092338 @default.
• W2095524269 hasConceptScore W2095524269C2775842073 @default.
• W2095524269 hasConceptScore W2095524269C2776694085 @default.
• W2095524269 hasConceptScore W2095524269C2777472916 @default.
• W2095524269 hasConceptScore W2095524269C2778822529 @default.
• W2095524269 hasConceptScore W2095524269C2779699572 @default.
• W2095524269 hasConceptScore W2095524269C2779984678 @default.
• W2095524269 hasConceptScore W2095524269C2781197716 @default.
• W2095524269 hasConceptScore W2095524269C2989005 @default.
• W2095524269 hasConceptScore W2095524269C535046627 @default.
• W2095524269 hasConceptScore W2095524269C55493867 @default.
• W2095524269 hasConceptScore W2095524269C71924100 @default.
• W2095524269 hasConceptScore W2095524269C86803240 @default.
• W2095524269 hasIssue "4" @default.
• W2095524269 hasLocation W20955242691 @default.
• W2095524269 hasLocation W20955242692 @default.
• W2095524269 hasLocation W20955242693 @default.

• next